FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295564194> ?p ?o ?g. }

• W4295564194 abstract "Background The emergence of PCSK9i (proprotein convertase subtilisin kexin type 9 inhibitor) and icosapent ethyl (IPE) has expanded the role of lipid‐lowering therapies beyond statins. Despite recommendations by clinical practice guidelines, their national eligibility and use rates remain unclear. Methods and Results In the National Health and Nutrition Examination Survey data from 2017 to 2020, we assessed eligibility and the use of statins, PCSK9i, and IPE among US adults according to American College of Cardiology/American Heart Association guideline recommendations. Eligibility for PCSK9i and IPE were determined in the following 2 scenarios: (1) assuming existing lipid‐lowering therapy as the maximum tolerated before assessing eligibility for novel therapies and (2) assessing eligibility after assuming initiation and maximal escalation of preexisting lipid‐lowering therapies and accounting for expected lipid improvements. Of 2729 sampled individuals, representing 149.3 million adults, 1376 had indications for statins, representing 65.8 million or 44.0% (95% CI, 40.9%–47.2%) of adults. Current statin use was 45% of those eligible and was low across demographic groups. A total of 9.7 and 11.6 million adults would benefit from PCSK9i and IPE, respectively, based on lipid profiles and existing therapies. Assuming maximal escalation of statins and addition of ezetimibe, 4.1% (95% CI, 2.8%–5.4%) of adults or 6.1 million would benefit from PCSK9i and 6.8% (95% CI, 5.4%–8.3%) or 10.2 million from IPE. Conclusions Six and 10 million individuals have clinical profiles whereby PCSK9i and IPE, respectively, would be expected to improve cardiovascular outcomes even after maximum escalation of statins and ezetimibe use, but remain undertreated with lipid‐lowering therapies. Optimal use of lipid‐targeted agents that include these novel agents is needed to improve population health outcomes." @default.
• W4295564194 created "2022-09-14" @default.
• W4295564194 creator A5010571732 @default.
• W4295564194 creator A5017974764 @default.
• W4295564194 creator A5018180754 @default.
• W4295564194 creator A5019311663 @default.
• W4295564194 creator A5072663918 @default.
• W4295564194 date "2022-09-20" @default.
• W4295564194 modified "2023-10-16" @default.
• W4295564194 title "Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States" @default.
• W4295564194 cites W2013818621 @default.
• W4295564194 cites W2017602185 @default.
• W4295564194 cites W2019071303 @default.
• W4295564194 cites W2044621072 @default.
• W4295564194 cites W2057674977 @default.
• W4295564194 cites W2116404316 @default.
• W4295564194 cites W2141898196 @default.
• W4295564194 cites W2168536722 @default.
• W4295564194 cites W2330820172 @default.
• W4295564194 cites W2511907480 @default.
• W4295564194 cites W2552545843 @default.
• W4295564194 cites W2596179513 @default.
• W4295564194 cites W2740472173 @default.
• W4295564194 cites W2765432372 @default.
• W4295564194 cites W2766278264 @default.
• W4295564194 cites W2767371454 @default.
• W4295564194 cites W2807844095 @default.
• W4295564194 cites W2899669642 @default.
• W4295564194 cites W2899889410 @default.
• W4295564194 cites W2899997727 @default.
• W4295564194 cites W2900034165 @default.
• W4295564194 cites W2909842054 @default.
• W4295564194 cites W2916068410 @default.
• W4295564194 cites W2918880809 @default.
• W4295564194 cites W2921012991 @default.
• W4295564194 cites W2923928888 @default.
• W4295564194 cites W2941101173 @default.
• W4295564194 cites W2948233520 @default.
• W4295564194 cites W2983052551 @default.
• W4295564194 cites W2985476501 @default.
• W4295564194 cites W2987000681 @default.
• W4295564194 cites W2987665527 @default.
• W4295564194 cites W2987868385 @default.
• W4295564194 cites W3001764054 @default.
• W4295564194 cites W3017405828 @default.
• W4295564194 cites W3021163647 @default.
• W4295564194 cites W3044850373 @default.
• W4295564194 cites W3085335913 @default.
• W4295564194 cites W3087678302 @default.
• W4295564194 cites W3111835680 @default.
• W4295564194 cites W3152340772 @default.
• W4295564194 cites W3159373679 @default.
• W4295564194 cites W3160152094 @default.
• W4295564194 cites W3170272938 @default.
• W4295564194 cites W4200612495 @default.
• W4295564194 cites W4213143341 @default.
• W4295564194 cites W4236673002 @default.
• W4295564194 doi "https://doi.org/10.1161/jaha.122.026075" @default.
• W4295564194 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36102276" @default.
• W4295564194 hasPublicationYear "2022" @default.
• W4295564194 type Work @default.
• W4295564194 citedByCount "2" @default.
• W4295564194 countsByYear W42955641942023 @default.
• W4295564194 crossrefType "journal-article" @default.
• W4295564194 hasAuthorship W4295564194A5010571732 @default.
• W4295564194 hasAuthorship W4295564194A5017974764 @default.
• W4295564194 hasAuthorship W4295564194A5018180754 @default.
• W4295564194 hasAuthorship W4295564194A5019311663 @default.
• W4295564194 hasAuthorship W4295564194A5072663918 @default.
• W4295564194 hasBestOaLocation W42955641941 @default.
• W4295564194 hasConcept C126322002 @default.
• W4295564194 hasConcept C142724271 @default.
• W4295564194 hasConcept C2776839432 @default.
• W4295564194 hasConcept C2778114629 @default.
• W4295564194 hasConcept C2778163477 @default.
• W4295564194 hasConcept C2778657065 @default.
• W4295564194 hasConcept C2780072125 @default.
• W4295564194 hasConcept C2780182762 @default.
• W4295564194 hasConcept C2780745583 @default.
• W4295564194 hasConcept C71924100 @default.
• W4295564194 hasConceptScore W4295564194C126322002 @default.
• W4295564194 hasConceptScore W4295564194C142724271 @default.
• W4295564194 hasConceptScore W4295564194C2776839432 @default.
• W4295564194 hasConceptScore W4295564194C2778114629 @default.
• W4295564194 hasConceptScore W4295564194C2778163477 @default.
• W4295564194 hasConceptScore W4295564194C2778657065 @default.
• W4295564194 hasConceptScore W4295564194C2780072125 @default.
• W4295564194 hasConceptScore W4295564194C2780182762 @default.
• W4295564194 hasConceptScore W4295564194C2780745583 @default.
• W4295564194 hasConceptScore W4295564194C71924100 @default.
• W4295564194 hasIssue "18" @default.
• W4295564194 hasLocation W42955641941 @default.
• W4295564194 hasLocation W42955641942 @default.
• W4295564194 hasLocation W42955641943 @default.
• W4295564194 hasOpenAccess W4295564194 @default.
• W4295564194 hasPrimaryLocation W42955641941 @default.
• W4295564194 hasRelatedWork W1989343587 @default.
• W4295564194 hasRelatedWork W2292681792 @default.
• W4295564194 hasRelatedWork W2328723245 @default.
• W4295564194 hasRelatedWork W2613263923 @default.

• next